Clinical Trial Update: Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

View source ↗

Summary

Post-marketing surveillance update for Calquence (acalabrutinib) in relapsed or refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma) | Status: COMPLETED